Brief: Eloxx Pharmaceuticals Provides Enrollment Update For Ongoing Phase 2 Clinical Studies For Cystic Fibrosis
06/07/2021 21:17
July 6 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS PROVIDES ENROLLMENT UPDATE FOR
ONGOING
PHASE 2 CLINICAL STUDIES FOR CYSTIC FIBROSIS
* ELOXX PHARMACEUTICALS INC - BASED ON ENROLLMENT TO DATE,
ELOXX
EXPECTS TO PRESENT DATA FROM FIRST FOUR TREATMENT ARMS OF STUDY
IN Q4 OF THIS YEAR
* ELOXX PHARMACEUTICALS INC - ELOXX WILL CONTINUE TO ENROLL
ADDITIONAL PATIENTS TO SUPPORT PHASE 3 CLINICAL TRIAL PLANNING
Source text for Eikon: ID:nGNX9hcQK0
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome